Benjamin P. Saylor

Senior author Kevin Ginsburg, MD, said he and his coauthors observed wide variation by practice in the use of active surveillance in this patient population.

The median time between PSA progression and metastasis was 7.0 months for darolutamide compared with 5.6 months for placebo.

“Darolutamide, unlike enzalutamide, does not affect cabazitaxel systemic exposure, justifying their use in combination,” the authors wrote in their poster.

“The clinical implications are that lutetium PSMA has similar overall survival to cabazitaxel, a proven life-prolonging therapy, but with fewer adverse events and better patient-reported outcomes," said Michael S. Hoffman, MBBS (Hons), FRACP, FAANMS.

“Overall, these data…provide new insights about survival in patients receiving avelumab first-line maintenance in the JAVELIN Bladder 100 trial with or without second-line treatment," says Joaquim Bellmunt, MD, PhD.

"This study does not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer,” said Robert J. Jones, MA, PhD, MBChB.

The investigators report that no device or procedure-related serious adverse events have occurred.

“With proper training and proper technique, there really can be drastic changes that can be made without having to do a surgical intervention,” commented first author Alissa Tyler, RN.

The hematuria monitor (HM) was discussed in a late-breaking abstract at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

At 2, 3, and 5 weeks after surgery, the stone removal rate was higher in the test group vs the control group (P < .05).

“Our results showed significant improvement in postoperative urgency and UUI (P = .005) with no significant change in IIEF-5 score at 6-month follow-up compared to baseline,” wrote the authors.

In this interview, Christopher L. Amling, MD, FACS, discusses the development of anatomic radical prostatectomy and how the technique transformed the surgical treatment of prostate cancer.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder.

In this installment of our 50th Anniversary Innovation Celebration, Anthony Zietman, MD, discusses the development of radiation therapy for prostate cancer.

"It’s important to recognize that there has been a shift in the way we approach ADT," says David F. Jarrard, MD.

"Overall, these findings tell us that not everyone can undergo a same-day surgery for BPH," says Michael A. Palese, MD.

“I think that this updated analysis of KEYNOTE-564 further supports adjuvant pembrolizumab as a new standard of care for patients with RCC with high risk of recurrence,” said Toni K. Choueiri, MD.

“I think what we're showing here is that the overall survival benefit, as well as the safety analysis, regardless of the number of comorbidities, was rather significant,” said study coauthor Neal D. Shore, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

The investigators reported that overall perioperative transfusion rates were significantly lower in patients undergoing robot-assisted radical cystectomy.

“Using a national cohort of older adults with dementia, we…found that donepezil was associated with a 13% increased risk of OAB compared to rivastigmine,” says study author Rajender R. Aparasu, PhD

“We’ll be able to take a drop of blood in a community setting such as a barbershop and be able to deliver results in 10 to 15 minutes right there,” says investigator Saurabh Mehta, ScD.

Pavlos Msaouel, MD, PhD, discusses the latest developments with adjuvant therapy in nonmetastatic renal cell carcinoma.

The investigators found that the overall upstaging rate from re-TURBT to RC was 34.9%, with 31.0% upstaged in the NAC group and 37.0% in the no-NAC group (P = .584).

Eggener addresses the NCCN’s reversal on its controversial decision to remove the word “preferred” from its guideline on active surveillance for low-risk prostate cancer.

“This post hoc analysis demonstrates that enzalutamide plus ADT provides clear clinical benefits in improving survival, delaying progression, and other secondary end points in patients with oligometastatic disease,” says Andrew J. Armstrong, MD, MSc.

“These findings are exciting because we’re challenging the dogma in radiation oncology that RCC is biologically radioresistant," ,” said lead author Chad Tang, MD.

“After 2 years, patients reported no increase in urinary or bowel side effects with the shorter course and its effectiveness was comparable,” said Mark Buyyounouski, MD.

According to the investigators, their findings were consistent with initial real-world experience with oral testosterone undecanoate indicating that dose titration is not required in most patients.